TSC2 C-term Antibody (GWB-70BF38)



0.1 ml


Clone ID: Y320

Immunogen: A synthetic peptide corresponding to residues in the C-term of human TSC2 was used as an immunogen. Predicted to detect isoform 2-4 based on sequence homology. Specificity: A synthetic peptide corresponding to residues in the C-term of human TSC2 was used as an immunogen. Predicted to detect isoform 2-4 based on sequence homology. Dilution: WB: 1:200-1000
IHC: 1:50
FC: 1:50. Tuberous sclerosis complexe-2 (TCS2 also known as Tuberin) is a tumor suppressor that form a complex with TSC1 (Hamartin ) and this complex is known to control various cellular functions including cell cycle, endocytosis, adhesion, and transcription (1). The C-terminal region of TSC2 contains a GTPase-activating protein (GAP) domain which interacts with Rap1, Rab5 and Rheb (2). The TSC1/TSC2 complex inhibits phosphorylation of S6kinase and 4E-BP1 through inactivation of mTOR (3). Additionally, binding of 14-3-3 beta to TSC2 at Ser1210 reduce the ability of the complex to inhibit phosphorylation of S6 kinase (4). Phosphorylation by ATK at Ser924 and Thr1518 inactivates TSC2 and disrupts its interaction with TSC1 (5). Tuberous sclerosis (TSC), an autosomal dominant disorder that affects 1 in 6000 individuals, is caused by a mutation in either the TSC1 or TSC2 tumor suppressor gene. 1. Klein UR, Haindl M, Nigg EA, et al, RanBP2 and SENP3 function in a mitotic SUMO2/3 conjugation-deconjugation cycle on Borealin ,Mol. Biol. Cell 20 (2009) 410 - 418
[Application: WB]
2. Horwitz KB, Dye WW, Harrell JC, et al, Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts ,PNAS 105 (2008) 5774-5779
[Application: IHC]
3. Nery FC, Zeng J, Niland BP, et al, TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton ,J Cell Sci 121 (2008) 3476-3486
[Application: WB]
4. Kim WY, Chang DJ, Hennessy B, et al, A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy ,Cancer Prev Res 1 (2008) 577-587
[Application: WB]
5. Blando J, Portis M, Benavides F, et al, PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth ,Am J Pathol 174 (2009) 1869-1879
[Application: WB]
6. Alexander A, Cai SL, Kim J, et al, ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS ,Proc Natl Acad Sci U S A 107 (2010) 4153-4158
[Application: WB]
7. Dere R, Wilson PD, Sandford RN, et al, Carboxy Terminal Tail of Polycystin-1 Regulates Localization of TSC2 to Repress mTOR ,PLoS One 5 (2010) e9239
[Application: WB]
1. Lamb,et al. Nature Cell Biol. 2: 281-287
2. Xiao et al J. Biol. Chem. 272: 6097-6100
3. Manning, B. D.; Tee, A. R.; Logsdon, M. N.; Blenis, J.; Cantley, L. C. : Molec. Cell 10: 151-162, 2002.
4. Shumway, S. D.; Li, Y.; Xiong, Y. : J. Biol. Chem. 278: 2089-2092, 2003.
5. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.-L. : 4: 648-657, 2002.
6. Manufactured under U.S. Patents, No. 5,675,063 and 7,429,487

Additional Information

Name TSC2 C-term Antibody (GWB-70BF38)
Availability Discontinued
Related Product Names TSC2, C-term Rabbit Monoclonal Antibody TSC2, TSC4, Tuberin, Tuberous sclerosis 2 proteinTSC2, C-term
Swissprot ID P49815
Molecular Weight 180 kDa
Source Rabbit
Application WB, IHC, FC
Clonality Monoclonal
Reactivity Human, Mouse, Rat
Storage Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
Datasheets/Manuals Printable datasheet for GWB-70BF38
Intended Use Research Use Only